Novel Pathways in Ischemic Stroke in Sickle Cell Anemia
镰状细胞贫血症缺血性中风的新途径
基本信息
- 批准号:10200126
- 负责人:
- 金额:$ 51.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdhesionsAffectAllelesAnimal ModelBiochemicalBiologicalBiological AssayBiomimeticsBlood PlateletsBlood TransfusionCandidate Disease GeneCaringCell LineChronicClinicalCodeComplexComplicationDataDevelopmentDiphosphatesDiseaseEndothelial CellsEndotheliumEnzymesExpression ProfilingFunctional disorderFundingGenesGeneticGenetic TranscriptionGoalsGolgi ApparatusHeritabilityHydrolysisIn VitroInflammatoryInjuryInsulin ReceptorInterventionIschemic StrokeKineticsLinkLipidsLiquid substanceMaintenanceMeasuresMediatingMediator of activation proteinMicrofluidicsMissense MutationModelingModificationMolecularMutationOutputPathogenesisPathway interactionsPatientsPediatric HospitalsPhysiologicalPlasmaProcessPrognosisProtein Activation PathwayProtein SecretionProteinsProteomicsPublic HealthReceptor SignalingRecurrenceReportingResearchResourcesRiskRoleSamplingSickle Cell AnemiaSignal TransductionSorting - Cell MovementStenosisStrokeStroke preventionStructural ProteinStructureSystemTestingTexasThrombosisThrombusVariantVascular DiseasesVascular Endotheliumcalcificationcerebrovascularcohortexome sequencinggenetic variantgenome wide association studyhigh resolution imaginghydroxyureaimprovedmonocytenovelnovel therapeuticspediatric patientsprotein expressionprotein transportresponseshear stressstroke riskstroke therapytargeted treatmenttheoriesthromboticvon Willebrand Factor
项目摘要
Stroke is a devastating complication of sickle cell anemia (SCA) that will occur in ~11% of all patients without
intervention. In pediatric patients with SCA, most of these strokes are ischemic and strongly linked with arterial
vasculopathy. There is a strong heritable component that affects development of stroke in SCA patients.
However, our understanding of the genes involved is very limited. Our group reported an unbiased genome wide
association study of stroke in SCA using whole exome sequencing. We identified and validated two particular
missense mutations in the GOLGB1 (Y1212C) and ENPP1 (K173Q) genes as being protective against stroke in
SCA. Our study goal is to define the functional role of GOLGB1 and ENPP1 as modulators of vascular endothelial
injury and ischemic stroke risk.
We have previously observed that: a) GOLGB1 levels affect Golgi structure in monocytes and endothelial
cells; b) The GOLGB1 Y1212C variant is associated with more dispersed Golgi in monocytes isolated from SCA
patients; and c) ENPP1 enzymatic activity is higher in SCA patients with the protective K allele of the ENPP1
K173Q variant. From this preliminary data, we hypothesize that 1) GOLGB1 affects Golgi structure, which in turn
regulates secretory output of pro-thrombotic factors such as von Willebrand factor (vWF) that can affect stroke
in SCA; and 2) that ENPP1 affects risk of thrombosis either through endothelial cell signaling or by hydrolysis of
the pro-inflammatory ATP inorganic pyrophosphate (PPi). We plan to test these hypotheses by analyzing the
function of GOLGB1 and ENPP1 in samples from patients with SCA. We will isolate primary monocyte and
endothelial cells from a large cohort of SCA patients receiving care at Texas Children’s Hospital.We will test our
central hypotheses by pursuing three aims: Aim 1: Examine the role of GOLGB1 in the structure and function of
Golgi complexes in sickle cell anemia - We will use high resolution imaging to determine the role of GOLGB1 in
maintaining Golgi structure and protein trafficking in monocyte and endothelial cells from SCA patients; Aim 2:
Determine the effect of ENPP1 activity in sickle cell anemia - We will measure plasma and endothelial activity of
the ENPP1 enzyme.We will also test whether ENPP1 modulates vascular dysfunction in patients with SCA; Aim
3: Determine impact of GOLGB1 and ENPP1 on endothelial activation in a microfluidic arterial model - We will
combine thrombotic protein assays and RNA expression profiling to identify endothelial activation pathways
affected by our candidate genes.
Our proposed studies will characterize the functional impact of our two genes and their genetic variants
in SCA patient samples. This will benefit our understanding of the pathophysiological pathways of stroke and
potentially provide targets for drug therapy to prevent or treat stroke in SCA patients.
中风是镰状细胞性贫血 (SCA) 的一种破坏性并发症,约 11% 的无症状患者会发生中风。
干涉。在患有 SCA 的儿科患者中,大多数中风是缺血性的,并且与动脉粥样硬化密切相关。
血管病变。有一个很强的遗传因素会影响 SCA 患者中风的发生。
然而,我们对所涉及基因的了解非常有限。我们的小组报告了全基因组的公正性
使用全外显子组测序进行 SCA 中风的关联研究。我们确定并验证了两个特定的
GOLGB1 (Y1212C) 和 ENPP1 (K173Q) 基因的错义突变可预防中风
斯卡。我们的研究目标是确定 GOLGB1 和 ENPP1 作为血管内皮细胞调节剂的功能作用
受伤和缺血性中风的风险。
我们之前观察到: a) GOLGB1 水平影响单核细胞和内皮细胞的高尔基体结构
细胞; b) GOLGB1 Y1212C 变体与从 SCA 分离的单核细胞中更分散的高尔基体相关
患者; c) 具有 ENPP1 保护性 K 等位基因的 SCA 患者中 ENPP1 酶活性较高
K173Q 变体。根据这些初步数据,我们假设 1) GOLGB1 影响高尔基体结构,进而影响高尔基体结构
调节促血栓形成因子的分泌输出,例如可影响中风的血管性血友病因子 (vWF)
在SCA; 2) ENPP1 通过内皮细胞信号传导或通过水解影响血栓形成的风险
促炎 ATP 无机焦磷酸盐 (PPi)。我们计划通过分析来检验这些假设
SCA 患者样本中 GOLGB1 和 ENPP1 的功能。我们将分离原代单核细胞和
来自德克萨斯儿童医院接受护理的一大群 SCA 患者的内皮细胞。我们将测试我们的
通过追求三个目标来提出中心假设: 目标 1:检查 GOLGB1 在结构和功能中的作用
高尔基复合体在镰状细胞性贫血中的作用 - 我们将使用高分辨率成像来确定 GOLGB1 在镰状细胞性贫血中的作用
维持 SCA 患者单核细胞和内皮细胞的高尔基体结构和蛋白质运输;目标 2:
确定 ENPP1 活性对镰状细胞性贫血的影响 - 我们将测量血浆和内皮活性
ENPP1酶。我们还将测试ENPP1是否调节SCA患者的血管功能障碍;目的
3:确定 GOLGB1 和 ENPP1 对微流体动脉模型中内皮激活的影响 - 我们将
结合血栓蛋白测定和 RNA 表达谱来识别内皮激活途径
受我们候选基因的影响。
我们提出的研究将描述我们的两个基因及其遗传变异的功能影响
SCA 患者样本中。这将有助于我们了解中风和中风的病理生理途径
可能为预防或治疗 SCA 患者中风的药物治疗提供目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan Michael Flanagan其他文献
Jonathan Michael Flanagan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathan Michael Flanagan', 18)}}的其他基金
NOVEL PATHWAYS IN ISCHEMIC STROKE IN SICKLE CELL ANEMIA
镰状细胞性贫血缺血性中风的新途径
- 批准号:
9565807 - 财政年份:2017
- 资助金额:
$ 51.6万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 51.6万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 51.6万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 51.6万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 51.6万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 51.6万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 51.6万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 51.6万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 51.6万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 51.6万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 51.6万 - 项目类别:














{{item.name}}会员




